This gap is due to funding limitations for clinical trials and the number of investigators with the expertise to lead these endeavors to rigorously evaluate the safety and efficacy of NRF2 activators in SCD. This evidence concerns the gene NFE2L2 and Schnyder corneal dystrophy.